Endometriosis - Pipeline Assessment and Market Forecasts to 2017

Endometriosis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Endometriosis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global endometriosis market. The report identifies the key trends shaping and driving the global endometriosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global endometriosis market was valued at $785m in 2009 and will grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $1.1 billion by 2017. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market is weak due to a lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. The endometriosis market is primarily formed of generic and off-label drugs and has very few approved drugs which fall in the major therapeutic categories such as NSAIDs, oral contraceptives, GnRH agonists and progestins.

Scope

The report provides information on the key drivers and challenges of the endometriosis market. Its scope includes:

• Annualized global endometriosis market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as GnRH antagonists, GnRH synergists, aromatase inhibitors, antiprogestins and steroid sulfatase inhibitors.
• Analysis of the current and future competition in the global endometriosis market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, Neurocrine Biosciences Inc., Æterna Zentaris Inc. and Repros Therapeutics Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometriosis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global endometriosis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global endometriosis market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ENDOMETRIOSIS: INTRODUCTION

2.1 GlobalData Pipeline Report Guidance

3 ENDOMETRIOSIS: MARKET CHARACTERIZATION

3.1 Endometriosis Therapeutics Market Size
3.2 Endometriosis Therapeutics Market Forecast and CAGR
3.3 Drivers and Barriers for the Endometriosis Therapeutics Market
  3.3.1 Drivers for Endometriosis Therapeutics Market
  3.3.2 Barriers for the Endometriosis Therapeutics Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 THE ENDOMETRIOSIS THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Therapies in the Endometriosis Therapeutics Market
  4.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Endometriosis
  4.3.2 Gonadotropin-Releasing Hormone (GnRH) agonists
  4.3.3 Birth Control Hormones for Endometriosis
  4.3.4 Progestins for Endometriosis
  4.3.5 Danazol
4.4 Key Takeaway

5 ENDOMETRIOSIS THERAPEUTICS MARKET: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Endometriosis Therapeutics – Promising Drugs Under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
  5.4.1 Visanne
  5.4.2 Proellex
  5.4.3 Elagolix
  5.4.4 MPI-676
5.5 Endometriosis Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.6 Endometriosis Disease Pipeline – Pipeline by Phase of Clinical Development
  5.6.1 Endometriosis Therapeutics – Recently Approved Products
  5.6.2 Endometriosis Therapeutics – Phase II Pipeline
  5.6.3 Endometriosis Therapeutics – Phase I Pipeline
  5.6.4 Endometriosis Therapeutics – Preclinical Pipeline
5.7 Key Takeaway

6 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION


7 ENDOMETRIOSIS: FUTURE PLAYERS IN ENDOMETRIOSIS THERAPEUTICS MARKET

7.1 Introduction
7.2 Abbott Laborateries
  7.2.1 Company Overview
  7.2.2 Business Overview
7.3 Bayer AG
  7.3.1 Company Overview
  7.3.2 Business Description
7.4 Repros Therapeutics, Inc
  7.4.1 Company Overview
  7.4.2 Business Description
7.5 Meditrina Pharmaceuticals, Inc.
  7.5.1 Company Overview
7.6 Æterna Zentaris Inc.
  7.6.1 Company Overview
  7.6.2 Business Description

8 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: APPENDIX

8.1 Definitions
8.2 Scope of Pipeline Research
8.3 Abbreviations
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

LIST OF TABLES

Table 1: Endometriosis Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 2: Endometriosis Therapeutics Market, Global, Market Forecasts ($m), 2009–2017
Table 3: Endometriosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 4: Endometriosis Therapeutics – Recently Approved Products, 2010
Table 5: Endometriosis Therapeutics – Phase II Pipeline, 2010
Table 6: Endometriosis Therapeutics – Phase I Pipeline, 2010
Table 7: Endometriosis Therapeutics – Preclinical Pipeline, 2010
Table 8: Abbott Laborateries – Women’s Health Pipeline Products, 2010
Table 9: Bayer AG – Women’s Healthcare Pipeline Products, 2010
Table 10: Bayer AG – Endometriosis Pipeline Products, 2010
Table 11: Repros Therapeutics Inc. – Women’s Health Pipeline Products, 2010
Table 12: Meditrinia Pharmaceuticals Inc. – Women’s Health Pipeline Products, 2010
Table 13: AEterna Zentaris Inc. – Endometriosis Pipeline Products, 2010

LIST OF FIGURES

Figure 1: Endometriosis Therapeutics Market, Global, Revenue ($m), 2001–2009
Figure 2: Endometriosis Therapeutics Market, Global, Market Forecasts ($m), 2009–2017
Figure 3: Opportunity and Unmet Need in the Endometriosis Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Endometriosis, 2010
Figure 5: Technology Trends Analytic Framework of the Endometriosis Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Endometriosis Pipeline – Description, 2010
Figure 7: Endometriosis Therapeutics Market – Clinical Pipeline by Mechanism Of Action, 2010
Figure 8: Endometriosis Pipeline by Phase of Clinical Development, 2010
Figure 9: Endometriosis Therapeutics Market – Strategic Competitor Assessment, 2010
Figure 10: Endometriosis Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model Skip to top